VAR2 Pharmaceuticals to present new results at the AACR Annual meeting 2018

New significant data about chondroitin sulphate – the target for the VAR2 protein – in prostate cancer, will be presented on April 18th, at this year's AACR meeting in Chicago, IL. The work is presented in a poster entitled “Expression and regulation of chondroitin sulfate in prostate cancer” and is the result of work by our partners at Copenhagen University, Denmark and University of British Columbia, BC, Canada. Check out the abstract here.

AACR is the biggest cancer conference in the world that attracts representatives from both academia and industry.